This $10 million appropriation represents a landmark commitment by the federal government to invest in kidney cancer research and seek a cure for this disease.”
New York, NY (PRWEB) May 08, 2017
After 13 years advocating for increased funding for kidney cancer research, Action to Cure Kidney Cancer (ACKC) is excited to announce that Congress has approved and the President has signed the Consolidated Appropriations Act for the remainder of FY2017. This bill includes a $10 million line item for kidney cancer research under the Congressionally Directed Medical Research Programs (CDMRP). This represents the largest increase ever in the federal budget for kidney cancer research.
Kidney cancer strikes 64,000 Americans each year, and 14,400 succumb to the disease. Heretofore, kidney cancer researchers received, on average, $1 million per year since 2006 as part of the DoD's Peer Reviewed Cancer Research Programs - also due to ACKC's initiative. The $10 million will provide a shot in the arm to find a cure for this disease, research for which has been perennially underfunded as compared to other cancers. Dr. James Brugarolas, head of the Kidney Cancer Program at the University of Texas Southwestern (UTSW) said: “This $10 million appropriation represents a landmark commitment by the federal government to invest in kidney cancer research and seek a cure for this disease.”
ACKC is a grassroots organization established in 2003 by kidney cancer patients, their families, and caregivers. Together, we are working to raise awareness of kidney cancer and to ensure that it receives adequate public and private funding. This funding is required to identify and develop effective treatment modalities and to find a cure for this disease. ACKC works with government officials, research institutions, and other interested organizations and individuals to increase the level of funding for kidney cancer research. See http://www.ackc.org.